A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

By Jonathan W. Day, Nickki Ottaway, James T. Patterson, V. Gelfanov, D. Smiley, J. Gidda, H. Findeisen, D. Bruemmer, D. J. Drucker, N. Chaudhary and 15 more. Nature Chemical Biology, 2009

604 citations recorded by the source corpus.

Subfields: Endocrine and Autonomic Systems, Endocrinology, Diabetes and Metabolism, Pharmacology

View Paper: https://www.semanticscholar.org/paper/0a9ccbafb77953a10b878525e4bb9f4e7021852c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrine and Autonomic Systems

In Endocrinology, Diabetes and Metabolism

In Pharmacology

M. Blüher

Citations in the corpus

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “26 This marked a signi ﬁ cant advancement in obesity treatment research, especially in combining multiple drug targets.”
Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers (2019, methodology): “ing care that is concordantwith evidencebased guidelines (18); expanding the role of teams to implement more intensive disease management strategies (6,19,20); tracking medication-taking behavior at a systems level (21); redesigning the organization of the care process (22); implementing electronic ”
Pharmacology, physiology, and mechanisms of incretin hormone action. (2013, background): “molecule (Day et al., 2009; Pocai et al., 2009), may expand the domain of incretin-based therapies into new therapeutic areas and have important implications for the safe and effective”
Glucagon-like peptide 1 (GLP-1) (2019, result): “Both of these GLP-1/ glucagon co-agonists, one based on a glucagon-derived backbone [922] and the other based on an oxyntomodulin-derived sequence [923], had superior weight loss in obese rodents relative to matched analogs that were selective in activity towards GLP-1R.”
Metabolically Healthy Obesity (2020, background): “Tschöp led to the discovery of several peptides with varying degrees of GLP-1 and glucagon coagonism (106, 112).”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “Moreover, weekly administration of PEGylated peptides reduced adiposity and improved glucose tolerance in diet-induced obese mice [351] , and sustained GLP1/glucagon dual agonism reverses obesity in diet-induce obese mice [352] .”